The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

According to TS VERTEX, as of July 2025, the platform’s ecosystem has completed a comprehensive upgrade, integrating diverse asset classes including cryptocurrencies, stocks, foreign exchange ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including ...